SCHEMBL3866038

SCHEMBL3866038

O=C(Cl)c1cccc(C(=O)c2ccccc2)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.78
TDP1 Q9NUW8 1/20 0.78
L3MBTL1 Q9Y468 1/20 0.78
ALDH1A1 P00352 3/20 0.61
PBRM1 Q86U86 1/20 0.59
SRD5A2 P31213 1/20 0.52
MAPT P10636 2/20 0.50
PTGS1 P23219 2/20 0.50
CXCR1 P25024 2/20 0.50
CXCR2 P25025 2/20 0.50
PTGS2 P35354 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
RECQL P46063 1/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
CYP3A4 P08684 1/20 0.50
HPGD P15428 1/20 0.50
MAPK1 P28482 1/20 0.50
PMP22 Q01453 1/20 0.50
SLC22A6 Q4U2R8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4349236 0.93 ATM (0.65) ATMTDP1L3MBTL1ALDH1A1PBRM1
SCHEMBL11596560 0.91 ATM (0.64) ATMTDP1L3MBTL1ALDH1A1PBRM1
SCHEMBL10624502 0.89 ATM (0.67) ATMTDP1L3MBTL1ALDH1A1PBRM1
SCHEMBL28506897 0.89 ATM (0.67) ATMTDP1L3MBTL1ALDH1A1PBRM1
SCHEMBL135162 0.89 ATM (1.00) ATMTDP1L3MBTL1ALDH1A1PBRM1
SCHEMBL9324919 0.89 ATM (1.00) ATMTDP1L3MBTL1ALDH1A1PBRM1
Benzene SCHEMBL9243917 0.89 ALDH1A1 (0.57) ATMTDP1L3MBTL1ALDH1A1HPGD
SCHEMBL134300 0.86 ATM (0.95) ATMTDP1L3MBTL1ALDH1A1PBRM1
SCHEMBL134024 0.86 ATM (0.95) ATMTDP1L3MBTL1ALDH1A1PBRM1
SCHEMBL27510 0.86 ALDH1A1 (0.59) ATMTDP1L3MBTL1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1993014055-A1 PREPARATION OF 2,5-DICHLOROBENZOPHENONES MAXDEM INCORPORATED (US) 1993-07-22 WO claimed
US-5210313-A Friedel crafts aryloylation of 1,4-dichlorobenzene and Lewis acids MAXDEM INCORPORATED (US) 1993-05-11 US claimed
WO-2013055467-A2 METHODS AND COMPOSITIONS FOR BONDING SILICONE POLYMERS TO HAIR AND NAILS LIQWD, INC. (US) 2013-04-18 WO disclosed
CN-1353609-B Amide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES CO 2011-07-13 CN disclosed
US-20090023722-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY 2009-01-22 US disclosed
WO-2008131119-A2 COMPOSITION AND METHOD FOR CANCER TREATMENT AND PREVENTION ACROPOLIS PHARMACEUTICALS, INC. (US) 2008-10-30 WO disclosed
US-20080261898-A1 COMPOSITION AND METHOD FOR CANCER TREATMENT AND PREVENTION ACROPOLIS PHARMACEUTICALS, INC. 2008-10-23 US disclosed
US-20080261898-A1 COMPOSITION AND METHOD FOR CANCER TREATMENT AND PREVENTION ACROPOLIS PHARMACEUTICALS, INC. 2008-10-23 US disclosed
US-7393859-B2 Amide substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-07-01 US disclosed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
EP-1379525-B1 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMA INC (US) 2007-10-10 EP disclosed
EP-1210344-A1 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMACEUTICALS, INC. (US) 2002-06-05 EP disclosed
EP-1208104-A2 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES AGOURON PHARMACEUTICALS, INC. (US) 2002-05-29 EP disclosed
EP-1187613-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2002-03-20 EP disclosed
WO-2001016136-A2 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES AGOURON PHARMACEUTICALS, INC. (US) 2001-03-08 WO disclosed
WO-2001012627-A1 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMACEUTICALS, INC. (US) 2001-02-22 WO disclosed
WO-2000076505-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-12-21 WO disclosed
WO-1993014055-A1 PREPARATION OF 2,5-DICHLOROBENZOPHENONES MAXDEM INCORPORATED (US) 1993-07-22 WO disclosed
US-5210313-A Friedel crafts aryloylation of 1,4-dichlorobenzene and Lewis acids MAXDEM INCORPORATED (US) 1993-05-11 US disclosed
EP-0425134-A1 Condensed pyrrolo derivatives, process for their preparation and pharmaceutical compositions containing them YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1991-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023722-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES IFNG, IRF3, EIF2AK2 ATM 1312/4885TDP1 3705/4885L3MBTL1 2741/4885
US-20080261898-A1 COMPOSITION AND METHOD FOR CANCER TREATMENT AND PREVENTION VEGFA, MKI67, HDGF ATM 1033/4885TDP1 2844/4885L3MBTL1 3578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.